Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with ...
Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and ...
“It just sounded like a rave out there,” Rollins told ComicBook before being serenaded by fans as he arrived for the meet and greet. “But yeah, it’s going to be a party, man. Music’s blasting. It’s a ...
WWE and Nutrabolt officially announced their first-ever co-brand collaboration via a press release on Thursday, unveiling WWE-themed flavors of C4 Ultimate Pro-Workout Powder and C4 Ultimate Energy ...
Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients Phase 1 Dose Escalation Data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results